Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Survival of Patients with Primary Brain Tumor: A Data Analysis of 10 Years

Author(s): Shristy Verma, Rishabha Malviya* and Prerna Uniyal

Volume 30, Issue 15, 2024

Published on: 03 April, 2024

Page: [1129 - 1132] Pages: 4

DOI: 10.2174/0113816128306113240328050608

Price: $65

Abstract

Background: The prognosis for primary brain tumors, like other CNS tumors, can vary greatly based on several factors, such as treatment history, age and gender at diagnosis, ethnic background, and treatment plan.

Materials and Methods: A systematic review approach was used to gather relevant data from PubMed, ScienceDirect, Google Scholar, and other sources.

Results: The survival rate of primary brain tumors and other CNS tumors appears to be correlated with several variables, including treatment history, gender, age at evaluation, race/ethnicity, and treatment regimen; this emphasizes the importance of routinely updating epidemiological data on primary brain tumors to advance biological understanding.

Conclusion: This study draws attention to the variations in the median survival times of the various kinds of primary brain tumors, with oligodendroglioma having the longest median survival time (199 months, or approximately 16.6 years) and glioblastoma having the shortest (8 months).

Next »
[1]
Kruchko C, Ostrom QT, Gittleman H, Barnholtz-Sloan JS. The CBTRUS story: Providing accurate population-based statistics on brain and other central nervous system tumors for everyone. Neuro-oncol 2018; 20(3): 295-8.
[http://dx.doi.org/10.1093/neuonc/noy006] [PMID: 29471448]
[2]
Low JT, Ostrom QT, Cioffi G, et al. Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians. Neurooncol Pract 2022; 9(3): 165-82.
[http://dx.doi.org/10.1093/nop/npac015] [PMID: 35601966]
[3]
Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro-oncol 2021; 23(12): 31-315.
[http://dx.doi.org/10.1093/neuonc/noab200] [PMID: 34608945]
[4]
Epidemiology S, Results E. Surveillance epidemiology and end results (SEER) program. Cancer incidence rates adjusted for reporting delay. 2020. Available from: http://surveillance.cancer.gov/delay/ (Accessed January 17 2024).
[5]
Kruchko C, Gittleman H, Ruhl J, et al. Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors. Neurooncol Pract 2019; 6(5): 330-9.
[http://dx.doi.org/10.1093/nop/npz029] [PMID: 31555447]
[6]
Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro-oncol 2022; 24: v1-v95.
[http://dx.doi.org/10.1093/neuonc/noac202] [PMID: 36196752]
[7]
Islami F, Ward EM, Sung H, et al. Annual report to the nation on the status of cancer, part 1: National Cancer Statistics. J Natl Cancer Inst 2021; 113(12): 1648-69.
[http://dx.doi.org/10.1093/jnci/djab131] [PMID: 34240195]
[8]
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391(10125): 1023-75.
[http://dx.doi.org/10.1016/S0140-6736(17)33326-3] [PMID: 29395269]
[9]
Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci 2018; 54: 7-13.
[http://dx.doi.org/10.1016/j.jocn.2018.05.002] [PMID: 29801989]
[10]
Senders JT, Staples P, Mehrtash A, et al. An online calculator for the prediction of survival in glioblastoma patients using classical statistics and machine learning. Neurosurgery 2020; 86(2): E184-92.
[http://dx.doi.org/10.1093/neuros/nyz403] [PMID: 31586211]
[11]
Kang MJ, Won YJ, Lee JJ, et al. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2019. Cancer Res Treat 2022; 54(2): 330-44.
[http://dx.doi.org/10.4143/crt.2022.128] [PMID: 35313102]
[12]
Girardi F, Di Carlo V, Stiller C, et al. Global survival trends for brain tumors, by histology: Analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3). Neuro-oncol 2023; 25(3): 593-606.
[http://dx.doi.org/10.1093/neuonc/noac232] [PMID: 36215122]
[13]
Woo PYM, Yau S, Lam TC, et al. Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: A Hong Kong population level analysis over a 14-year period. Neurooncol Pract 2023; 10(1): 50-61.
[http://dx.doi.org/10.1093/nop/npac069] [PMID: 36659973]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy